vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and OneStream, Inc. (OS). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $163.7M, roughly 1.7× OneStream, Inc.). OneStream, Inc. runs the higher net margin — 0.6% vs -45.7%, a 46.3% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 23.6%). OneStream, Inc. produced more free cash flow last quarter ($25.6M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 21.8%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Blue Stream provides cable television, cable telephone, DVR, and up to 1 GIG Internet speed broadband services to customers in the Florida communities of Coral Springs and Weston.
GH vs OS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $163.7M |
| Net Profit | $-128.5M | $999.0K |
| Gross Margin | 64.6% | 69.8% |
| Operating Margin | -43.0% | -3.2% |
| Net Margin | -45.7% | 0.6% |
| Revenue YoY | 39.4% | 23.6% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $163.7M | ||
| Q3 25 | $265.2M | $154.3M | ||
| Q2 25 | $232.1M | $147.6M | ||
| Q1 25 | $203.5M | $136.3M | ||
| Q4 24 | $201.8M | $132.5M | ||
| Q3 24 | $191.5M | $129.1M | ||
| Q2 24 | $177.2M | $117.5M | ||
| Q1 24 | $168.5M | $110.3M |
| Q4 25 | $-128.5M | $999.0K | ||
| Q3 25 | $-92.7M | $-8.8M | ||
| Q2 25 | $-99.9M | $-18.4M | ||
| Q1 25 | $-95.2M | $-24.0M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $-171.9M | ||
| Q2 24 | $-102.6M | $-7.8M | ||
| Q1 24 | $-115.0M | $-5.0M |
| Q4 25 | 64.6% | 69.8% | ||
| Q3 25 | 64.7% | 68.1% | ||
| Q2 25 | 65.0% | 68.6% | ||
| Q1 25 | 63.3% | 68.0% | ||
| Q4 24 | 61.6% | 66.8% | ||
| Q3 24 | 61.1% | 50.1% | ||
| Q2 24 | 59.1% | 68.5% | ||
| Q1 24 | 61.2% | 69.1% |
| Q4 25 | -43.0% | -3.2% | ||
| Q3 25 | -37.3% | -11.3% | ||
| Q2 25 | -45.9% | -21.8% | ||
| Q1 25 | -54.6% | -29.3% | ||
| Q4 24 | -62.4% | -35.8% | ||
| Q3 24 | -61.3% | -197.6% | ||
| Q2 24 | -56.8% | -9.8% | ||
| Q1 24 | -59.2% | -4.9% |
| Q4 25 | -45.7% | 0.6% | ||
| Q3 25 | -35.0% | -5.7% | ||
| Q2 25 | -43.0% | -12.5% | ||
| Q1 25 | -46.8% | -17.6% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | -133.1% | ||
| Q2 24 | -57.9% | -6.7% | ||
| Q1 24 | -68.2% | -4.5% |
| Q4 25 | $-1.01 | — | ||
| Q3 25 | $-0.74 | — | ||
| Q2 25 | $-0.80 | — | ||
| Q1 25 | $-0.77 | — | ||
| Q4 24 | $-0.90 | — | ||
| Q3 24 | $-0.88 | $-1.06 | ||
| Q2 24 | $-0.84 | — | ||
| Q1 24 | $-0.94 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $693.6M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $504.7M |
| Total Assets | $2.0B | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $693.6M | ||
| Q3 25 | $580.0M | $653.9M | ||
| Q2 25 | $629.1M | $652.1M | ||
| Q1 25 | $698.6M | $593.9M | ||
| Q4 24 | $525.5M | $544.2M | ||
| Q3 24 | $585.0M | $495.5M | ||
| Q2 24 | $933.7M | $140.5M | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $504.7M | ||
| Q3 25 | $-354.5M | $472.1M | ||
| Q2 25 | $-305.5M | $458.2M | ||
| Q1 25 | $-250.8M | $412.9M | ||
| Q4 24 | $-139.6M | $386.2M | ||
| Q3 24 | $-60.1M | $458.2M | ||
| Q2 24 | $-1.6M | $97.5M | ||
| Q1 24 | $68.3M | $102.5M |
| Q4 25 | $2.0B | $1.0B | ||
| Q3 25 | $1.3B | $949.4M | ||
| Q2 25 | $1.3B | $910.5M | ||
| Q1 25 | $1.3B | $867.3M | ||
| Q4 24 | $1.5B | $823.2M | ||
| Q3 24 | $1.5B | $750.1M | ||
| Q2 24 | $1.6B | $379.7M | ||
| Q1 24 | $1.7B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $25.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $25.6M |
| FCF MarginFCF / Revenue | -19.3% | 15.7% |
| Capex IntensityCapex / Revenue | 9.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 25.79× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $95.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $25.8M | ||
| Q3 25 | $-35.4M | $5.0M | ||
| Q2 25 | $-60.3M | $29.7M | ||
| Q1 25 | $-62.7M | $36.2M | ||
| Q4 24 | $-64.5M | — | ||
| Q3 24 | $-51.1M | $2.4M | ||
| Q2 24 | $-94.0M | $8.1M | ||
| Q1 24 | $-30.3M | $25.5M |
| Q4 25 | $-54.2M | $25.6M | ||
| Q3 25 | $-45.8M | $4.8M | ||
| Q2 25 | $-65.9M | $29.4M | ||
| Q1 25 | $-67.1M | $35.8M | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | $1.3M | ||
| Q2 24 | $-99.1M | $7.7M | ||
| Q1 24 | $-37.2M | $24.9M |
| Q4 25 | -19.3% | 15.7% | ||
| Q3 25 | -17.3% | 3.1% | ||
| Q2 25 | -28.4% | 19.9% | ||
| Q1 25 | -33.0% | 26.3% | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | 1.0% | ||
| Q2 24 | -55.9% | 6.6% | ||
| Q1 24 | -22.1% | 22.5% |
| Q4 25 | 9.9% | 0.1% | ||
| Q3 25 | 3.9% | 0.1% | ||
| Q2 25 | 2.4% | 0.2% | ||
| Q1 25 | 2.2% | 0.3% | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | 0.8% | ||
| Q2 24 | 2.9% | 0.3% | ||
| Q1 24 | 4.1% | 0.6% |
| Q4 25 | — | 25.79× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
